Nephros, Inc. (NEPH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1158034,
    "name": "Nephros, Inc.",
    "stock_name": "Nephros, Inc.",
    "full_name": "Nephros, Inc.",
    "name_url": "stocks-analysis/nephros-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "5.79",
    "chg": 0.48,
    "chgp": "8.95%",
    "dir": 1,
    "prev_price": "5.31",
    "mcapval": "41.66",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US6406714005",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "25.13 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nephros-inc-1158034-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Nephros, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nephros-inc-overvalued-or-undervalued-3689263",
        "imagepath": "",
        "date": "2025-11-11 11:33:25",
        "description": "As of 7 November 2025, the valuation grade for Nephros, Inc. moved from attractive to very attractive, indicating a stronger outlook for the company. The stock is currently considered undervalued, with a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison to peers, Nephros has a PEG ratio of 0.23, while Nutriband, Inc. shows a negative P/E of -11.62, highlighting Nephros's relative strength in valuation metrics.\n\nDespite the lack of recent return data, Nephros's valuation ratios suggest it is positioned favorably within the Pharmaceuticals & Biotechnology sector. The company's ROCE of 13.86% and ROE of 8.62% further support its attractiveness in the market...."
      },
      {
        "title": "Is Nephros, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nephros-inc-overvalued-or-undervalued-3685067",
        "imagepath": "",
        "date": "2025-11-10 11:15:07",
        "description": "As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive. The company appears to be undervalued based on its current metrics. Key ratios include a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison, Nephros has a more favorable PEG ratio of 0.23 compared to its peer Nutriband, Inc., which has a negative P/E ratio and a PEG of 0.0000, indicating a significant valuation gap.\n\nWhile the stock has not provided return data for comparison, its recent valuation improvements suggest a positive outlook. Overall, Nephros, Inc. is positioned as an attractive investment opportunity within the Pharmaceuticals & Biotechnology sector...."
      },
      {
        "title": "Is Nephros, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nephros-inc-overvalued-or-undervalued-3683170",
        "imagepath": "",
        "date": "2025-11-09 11:08:45",
        "description": "As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation metrics. The company appears to be undervalued, supported by a P/E ratio of 36, a PEG ratio of 0.23, and an EV to EBITDA ratio of 31.89. In comparison, its peer Nutriband, Inc. has a P/E ratio of -11.62, highlighting Nephros's relatively stronger valuation position.\n\nDespite recent stock performance showing a significant decline of 19.30% over the past week compared to a 1.63% drop in the S&P 500, Nephros has delivered impressive returns year-to-date at 212.93%, significantly outperforming the S&P 500's 14.40%. This performance, combined with its attractive valuation ratios, suggests that Nephros, Inc. is positioned favorably in the market...."
      },
      {
        "title": "Is Nephros, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nephros-inc-overvalued-or-undervalued-3651072",
        "imagepath": "",
        "date": "2025-10-28 11:12:11",
        "description": "As of 24 October 2025, the valuation grade for Nephros, Inc. has moved from very attractive to attractive. Based on the current metrics, the company appears to be overvalued. The P/E ratio stands at 36, significantly higher than the peer average of approximately 31.39, while the EV to EBITDA ratio is also elevated at 31.89 compared to its peers. Additionally, the PEG ratio is notably low at 0.23, suggesting that the stock may not be growing at a pace that justifies its current valuation.\n\nIn comparison to its peers, Nephros, Inc. has a P/E ratio that exceeds Nutriband, Inc. at -11.62 and NeuroOne Medical Technologies Corp. at -6.96, both of which are considered risky. The company's ROCE of 13.86% and ROE of 8.62% indicate decent returns, but they do not sufficiently offset the high valuation ratios. While specific return data is not available, the absence of a strong performance relative to the S&P 500 furt..."
      }
    ],
    "total": 8,
    "sid": "1158034",
    "stock_news_url": "https://www.marketsmojo.com/news/nephros-inc-1158034"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Nephros, Inc. overvalued or undervalued?

2025-11-11 11:33:25

As of 7 November 2025, the valuation grade for Nephros, Inc. moved from attractive to very attractive, indicating a stronger outlook for the company. The stock is currently considered undervalued, with a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison to peers, Nephros has a PEG ratio of 0.23, while Nutriband, Inc. shows a negative P/E of -11.62, highlighting Nephros's relative strength in valuation metrics. Despite the lack of recent return data, Nephros's valuation ratios suggest it is positioned favorably within the Pharmaceuticals & Biotechnology sector. The company's ROCE of 13.86% and ROE of 8.62% further support its attractiveness in the market....

Is Nephros, Inc. overvalued or undervalued?

2025-11-10 11:15:07

As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive. The company appears to be undervalued based on its current metrics. Key ratios include a P/E ratio of 36, a Price to Book Value of 3.83, and an EV to EBITDA of 31.89. In comparison, Nephros has a more favorable PEG ratio of 0.23 compared to its peer Nutriband, Inc., which has a negative P/E ratio and a PEG of 0.0000, indicating a significant valuation gap. While the stock has not provided return data for comparison, its recent valuation improvements suggest a positive outlook. Overall, Nephros, Inc. is positioned as an attractive investment opportunity within the Pharmaceuticals & Biotechnology sector....

Is Nephros, Inc. overvalued or undervalued?

2025-11-09 11:08:45

As of 7 November 2025, the valuation grade for Nephros, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation metrics. The company appears to be undervalued, supported by a P/E ratio of 36, a PEG ratio of 0.23, and an EV to EBITDA ratio of 31.89. In comparison, its peer Nutriband, Inc. has a P/E ratio of -11.62, highlighting Nephros's relatively stronger valuation position. Despite recent stock performance showing a significant decline of 19.30% over the past week compared to a 1.63% drop in the S&P 500, Nephros has delivered impressive returns year-to-date at 212.93%, significantly outperforming the S&P 500's 14.40%. This performance, combined with its attractive valuation ratios, suggests that Nephros, Inc. is positioned favorably in the market....

Is Nephros, Inc. overvalued or undervalued?

2025-10-28 11:12:11

As of 24 October 2025, the valuation grade for Nephros, Inc. has moved from very attractive to attractive. Based on the current metrics, the company appears to be overvalued. The P/E ratio stands at 36, significantly higher than the peer average of approximately 31.39, while the EV to EBITDA ratio is also elevated at 31.89 compared to its peers. Additionally, the PEG ratio is notably low at 0.23, suggesting that the stock may not be growing at a pace that justifies its current valuation. In comparison to its peers, Nephros, Inc. has a P/E ratio that exceeds Nutriband, Inc. at -11.62 and NeuroOne Medical Technologies Corp. at -6.96, both of which are considered risky. The company's ROCE of 13.86% and ROE of 8.62% indicate decent returns, but they do not sufficiently offset the high valuation ratios. While specific return data is not available, the absence of a strong performance relative to the S&P 500 furt...

View All News